Table 1
| Â | M184V mutants N=7 | WT N=11 |
|---|---|---|
Median Age, yrs (range) | 30 (26.5-37) | 34 (21-38) |
African origin | 7 (100%) | 7 (64%) |
European origin | 0 | 2 (18%) |
Caribbean origin | 0 | 1 (9%) |
South American origin | 0 | 1 (9%) |
Median gestation at START initiation, completed weeks (range) | 22 (19-26) | 21 (15-29) |
Median duration START, days (range) | 115 (87-132) | 121 (68-151) |
Virological suppression at delivery | 6 (86%) (other VL 57c/ml) | 11 (100%) |
Subtype B | 1 (14%) | 4 (36%) |
Subtype C | 5 (72%) | 1 (9%) |
Subtype AG | 1 (14%) | 6 (55%) |
Previous ART | 2/7 (29%) | 3/11 (27%) |
Previous ART regimens | ZDVm, CBV/LPVr | ZDVm, CBV/nelfinavir, CBV/nelfinavir |
Population based sequencing performed | 7/7 (100%) | 10/11 (91%) (1 failed) |
WT on population based sequencing | 7/7 | 10/10 |
Number of Lopinavir TDM performed | 6/7 (86%) | 5/11 (45%) |
Median Lopinavir concentration (µg/L) (range) | 4446 (2791-7551) | 2991 (2023-7782) |
Subsequent ART | 4/7 (57%) | 3/11 (27%) |
Virological suppression with subsequent ART | 4/4 (100%) | 2/3 (67%) (1 stopped after a few weeks) |